Integrating Obesity Management Medications with Bariatric Surgery: A Surgeon's Guide

The Evolving Landscape of Obesity Care

• 💡 The integration of Obesity Management Medications (OMMs), particularly GLP-1 receptor agonists and dual GIP/GLP-1 agonists, is reshaping bariatric surgical practice.
• 🎯 Patients are increasingly presenting on these medications pre- and post-operatively, necessitating a combined approach rather than viewing surgery and medications as competing therapies.

Pharmacologic Classes and Efficacy

• 💊 GLP-1 receptor agonists (e.g., semaglutide, liraglutide) offer 5-12% total body weight loss (TBWL) via incretin-based satiety and delayed gastric emptying.
• 🚀 Dual GIP/GLP-1 agonists are more potent, achieving 15-22% TBWL.
• 🧠 Sympathomimetics (e.g., phentermine) provide modest weight loss (3-7% TBWL) through appetite suppression.
• ⚖️ Combination agents like bupropion-naltrexone and phentermine-topiramate offer 5-12% TBWL by targeting multiple pathways.
• ✨ Emerging therapies, including triple agonists and oral GLP-1s, show promising TBWL in trials.

Preoperative Integration and Challenges

• ⚠️ Patients benefiting from OMMs pre-operatively should not have their surgical candidacy compromised; surgery remains the most durable intervention.
• 🩺 Surgeons must manage delayed gastric emptying and aspiration risk by pausing weekly GLP-1s for at least one week pre-op.
• 🍎 Nutritional depletion, especially protein deficits exacerbated by appetite suppression, must be screened for and managed.
• 💸 Insurance often approves surgery but denies medication continuation, creating a significant barrier to coordinated care.

Postoperative OMM Implementation

• 🗓️ OMMs are typically introduced 6-12 months post-op, once diet stabilizes, though earlier initiation (4-6 weeks) may be considered for pediatric or high-risk populations.
• 💊 Injectable GLP-1s may be preferred post-surgery due to altered pharmacokinetics affecting oral agent absorption.
• ⚠️ Close monitoring for nutritional compromise, including protein intake, hydration, and micronutrient status, is crucial to prevent malnutrition.
• 📈 OMMs should be framed as tools for managing disease persistence or plateau, not as a marker of surgical failure.

Systems-Level Barriers and Coordinated Care

• 🌐 Inconsistent insurance coverage for long-term medical therapy, despite covering surgery, fragments care and undermines a chronic disease model.
• 🤝 Establishing shared-care pathways between bariatric surgery, obesity medicine, and primary care is essential to avoid fragmented care.
• 🗣️ Patient-centered language is vital, emphasizing complementary therapy rather than hierarchy or competition between surgery and medications.
• 📈 Aligning systems, messaging, and evidence is key to offering integrated, individualized treatment pathways for durable weight loss and improved metabolic health.